Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Modulating cell cycle: current applications and prospects for future drug development.

Hala Gali-Muhtasib1, Nadine Bakkar

  • 1Department of Biology, American University of Beirut, Beirut, Lebanon. amro@aub.edu.lb

Current Cancer Drug Targets
|December 10, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unveiling the antioxidant and anticancer potential of local mediterranean olive and fig extracts against breast cancer.

BMC complementary medicine and therapies·2026
Same author

Correction: Al Bitar et al. Thymoquinone Radiosensitizes Human Colorectal Cancer Cells in 2D and 3D Culture Models. <i>Cancers</i> 2022, <i>14</i>, 1363.

Cancers·2025
Same author

Transthyretin abnormalities in amyotrophic lateral sclerosis: High molecular weight species in cerebrospinal fluid and stromal deposits in choroid plexus.

Journal of neuropathology and experimental neurology·2025
Same author

Omics technologies as powerful approaches to unravel colorectal cancer complexity and improve its management.

Molecules and cells·2025
Same author

ONC206, an imipridone derivative, demonstrates anti-colorectal cancer activity against stem/progenitor cells in 3D cell cultures and in patient-derived organoids.

Pharmacological reports : PR·2024
Same author

Misfolded alpha-synuclein in amyotrophic lateral sclerosis: Implications for diagnosis and treatment.

European journal of neurology·2024
Same journal

Coordinated Roles of T Cells and Natural Killer Cells in Tumor Immunity.

Current cancer drug targets·2026
Same journal

Multi-omics Signature Predicts Anti-EGFR Therapy Benefit in Colorectal Cancer Liver Metastases: A Multi-center Cohort Study.

Current cancer drug targets·2026
Same journal

Anticancer Effect and Mechanism of Novel c-Myc Inhibitor BP1 on Hepatocellular Carcinoma.

Current cancer drug targets·2026
Same journal

Homoharringtonine Impedes Migration and Invasion by Inhibiting EphB4/SRI/EMT Signaling and Enhances the Antimetastatic Abilities of Erlotinib in Pancreatic Cancer.

Current cancer drug targets·2026
Same journal

Corrigendum to: Migrasomes: A Novel Target for Cancer Treatment.

Current cancer drug targets·2026
Same journal

Corrigendum to: GPX4 Inhibition Enhances the Antitumor Effect of PARP Inhibitor on Homologous Recombination Proficient Ovarian Cancer Cells.

Current cancer drug targets·2026
See all related articles

Cell cycle regulation involves proteins like cyclins and cyclin-dependent kinases (Cdks). Targeting these cell cycle molecules offers promising anticancer drug strategies.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • The cell cycle is a fundamental biological process controlling cell growth and division.
  • Dysregulation of cell cycle control genes is a hallmark of cancer development.
  • Key regulators include cyclins, cyclin-dependent kinases (Cdks), Cdk inhibitors (CKIs), p53, and pRb.

Purpose of the Study:

  • To review the basic regulatory machinery of cell cycle entry.
  • To highlight recent advances in cell cycle regulation research.
  • To discuss targeting cell cycle molecules, especially Cdks, for novel anticancer therapies.

Main Methods:

  • Literature review of cell cycle regulation.
  • Analysis of regulatory proteins and their roles in cell proliferation.

Related Experiment Videos

  • Discussion of therapeutic strategies targeting cell cycle checkpoints.

    • Main Results:

    • Identified key protein families (cyclins, Cdks, CKIs, p53, pRb) controlling cell cycle progression.
    • Demonstrated how deregulation of these proteins can lead to uncontrolled cell proliferation and cancer.
    • Highlighted specific cell cycle transitions (G1 to S, G2 to M) as critical targets.

    Conclusions:

    • Modulating cell cycle regulatory molecules presents a promising avenue for anticancer drug development.
    • Targeting Cdks offers a specific approach for novel and potentially more effective cancer treatments.
    • Several novel cell cycle-targeting agents are nearing or are in clinical trials.